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ABSTRACT 
Obsessive compulsive symptoms have been reported to occur in high proportion in 
schizophrenia. Presence of obsessive compulsive symptoms in schizophrenia has poor prognostic 
significance. Because of the antiobsessional effect of the fluoxetine, present study was undertaken 
as preliminary investigation in cases of schizophrenia with obsessive compulsive symptoms. We 
conducted an open trial of 12 weeks duration in which fluoxetine was added up to 80 mg to the 
maintenance neuroleptic medication of outpatients of schizophrenia with obsessive compulsive 
symptoms diagnosed by DSM-IV criteria. Five patients showed a significant reduction in scores of 
Positive and Negative Syndrome Scale, Yale Brown Obsessive Compulsive Scale and Clinical 
Global Impression Scale. Two patients did not show any response. Fluoxetine was well tolerated by 
all the patients. The positive findings of this preliminary investigation supports the further investigations 
of fluoxetine as potential treatment in the obsessive compulsive symptoms in schizophrenia. 
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The presence of obsessive compulsive 
(OC) symptoms in schizophrenic patients have 
been reported for decades. Recent studies have 
reported that OC symptoms occur in large 
number of schizophrenic patients varying from 
13-25% (Bermanetal.,1995; Cossofetal., 1998; 
Fenton & Mcglashan,1986). Presence of 
persistent OC symptoms represents an indicator 
of poor prognosis (Fenton & Mcglashan, 1986; 
Samuel et al.,1993). These patients have been 
reported to be more socially isolated, less likely 
to work and need longer hospitalization than non 
OC schizophrenic patients (Fenton & Mcglashan, 
1986; Samuel et al.,1993). Fluoxetine has been 
reported to improve negative symptoms when 
added to neuroleptics in schizophrenic patients 
(Goff et al.,1995). However, later studies have 
failed to find any improvement in positive or 
negative symptoms when fluoxetine was added 
to Clozapine and conventional antipsychotics 
(Arango et al.,2000). There are several case 
reports that described patients who showed 
improvement in OC symptoms when fluoxetine 
was added to their ongoing neuroleptic medication 
(Sewell et al.,1994, Tejera et al.,1994). However 
there is no study in literature that confirms the 
efficacy of fluoxetine in OC symptoms in 
schizophrenic patients. We report an open pilot 
study in which fluoxetine was added to the ongoing 
neuroleptic medication of schizophrenic patients 
with OC symptoms. 
MATERIAL AND METHOD 
Seven outpatients (6 male, 1 female) with 
mean±SD age 25.7±6.6 years (range 18-35 
years) were included in the study. The diagnosis 
of schizophrenia was confirmed by information 
from relatives of the patients, chart review and 
clinical interview of the patients using DSM-IV 
criteria. OC symptoms were diagnosed by 
Fenton and McGlashan (1986) criteria. Patients 
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with comorbid axis I disorders and clinically 
significant physical illness were excluded. 
Patients were stable on same dosage of their 
neuroleptic medication at least for one month 
prior to inclusion in the study. All the patients or 
their relatives (whichever applicable) gave 
written informed consent for participation in the 
study after being provided details of procedure. 
Detailed history was taken and physical 
examination was carried out. Routine blood 
investigations were carried out. Patients were 
assessed on Positive and Negative Syndrome 
Scale (PANSS; Kay et al., 1987), Yale Brown 
Obsessive Compulsive Scale (YBOCS; 
Goodman et al., 1989), Clinical Global 
Impression scale (CGI; NIMH 1985) and Dosage 
Record Treatment Emergent Symptom Scale 
(DOTES; Campbell and Palij 1985) at baseline 
and thereafter at every two weeks throughout the 
study period of 12 weeks. All the scales were 
administered to the patients by one clinician (first 
author) throughout the study. 20 mg fluoxetine 
was added to their neuroleptic medication in first 
two weeks then increased to 40 mg from 3rd week, 
thereafter doses of fluoxetine were increased on 
the basis of clinical judgement to 60 mg from 5th 
week and 80 mg from 9th week. Compliance was 
ensured through counselling of the patient and 
family members taking care of the patient. Drugs 
were administered to the patient daily under direct 
supervision of close family member taking care 
of the patient. Baseline scores of PANSS, YBOCS 
and CGI were compared with the final scores at 
12th week using paired t' test (two tailed). 
RESULTS 
All the patients completed the study period 
of 12 weeks. Mean duration of illness was 
7.35±4.9 years. Mean dose of fluoxetine was 74 
mg/day (range 40-80 mg). The antipsychotics 
given to the patients were haloperidol (n=1), 
trifluoperazine (n=1), injection fluphenazine 
(n=1), risperidone (n=3) and clozapine (n=1). 
Concomittant medication given were 
antiparkinsonian (n=3) and benzodiazepine 
(n=1). Five patients showed response in both 
OC and schizophrenic symptoms while 2 did not 
show any response. 
Ratings on YBOCS (Table) at 12 weeks 
showed a significant improvement (p <01) as 
compared to baseline. Total scores on PANSS 
also showed a significant improvement (p<.004). 
Further analysis of PANSS subscales showed 
significant improvement in positive symptoms 
(p<.01), negative symptoms (p<.006) and 
general psychopathology (p<.004) as compared 
to baseline. Score of severity of illness on CGI 
showed a significant reduction (p<.01). Ratings 
of patients on CGI global improvement of 
individual patient showed very much 
improvement in 1, much improvement in 3, 
minimal improvement in 1 and no change in 2 
patients. All patients tolerated fluoxetine well. 
TABLE 
SCORES AT BASELINE AND 12TH WEEK 
Scales 
YBOCS 
PANSS 
Positive 
Negative 
General 
Psychopathology 
Total 
CGI 
Severity of illness 
Baseline 
Mean±SD 
30.3±4.9 
10.0±1.7 
16.7±7.1 
28.1 ±2.8 
54.8±8.6 
5.5±0.8 
12th Week 
Mean±SD 
14l±10.9 
7.7±1.5 
14.1±7.7 
23.0±4.7 
44.8±13.0 
3.8±1.6 
P 
0.01 
0.01 
0.006 
0.004 
0.004 
0.01 
YBOCS : Yale Brown Obsessive Compulsive Scale, 
PANSS: Positive and Negative Syndrome Scale, 
CGI: Clinical Global Impression 
Two patients developed restlessness and 
palpitation in first week which subsided in one 
week. Two patients complained of mild anorexia 
while one developed moderate anorexia which 
gradually decreased after four weeks. Two 
patients developed mild tremors and occasional 
headache tolerance to which developed in four 
weeks. None of the patient developed worsening 
of psychotic symptoms. 
DISCUSSION 
Evidence from this preliminary open trial 
suggest that fluoxetine was effective in reducing 
OC symptoms in schizophrenic patients. An 
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improvement in residual schizophrenic 
symptoms was also observed. It also improved 
the global picture of the schizophrenic patients. 
The findings are interesting with the current 
evidence of dysfunction of serotonin in 
schizophrenia (Roth & Meltzer,1995) and 
obsessive compulsive disorder (Pigott,1996). 
Also OC symptoms respond to serotonergic 
drugs like fluoxetine (Montgomery et al.,1993, 
Tollofson et al.,1994) and clomipramine 
(Clomipramine Collaborative Study Group 
1991). Findings of our study suggest that OC 
symptoms in schizophrenic patients respond to 
fluoxetine in much the same way as OC 
symptoms in non schizophrenic patients. The 
improvement in residual schizophrenic 
symptoms is less clear. One possible explanation 
for improvement in schizophrenic symptoms 
could be the increase in the blood levels of 
neuroleptics because fluoxetine may increase 
the blood levels by inhibition of cytochrome p450 
2d6 enzyme (Arango et al.,2000; Jefferson, 
1998). As other than two non- responders none 
of the patient was treatment resistant so higher 
dose of neuroleptics may cause an improvement 
in schizophrenic symptoms. Improvement in 
general symptoms could be explained by 
reduction in depression and anxiety associated 
with obsession. Another possible mechanism of 
improvement in schizophrenic symptoms could 
be the effect of serotonin on dopaminergic 
system as there is evidence that serotonin may 
modulate dopaminergic system physiologically 
at various levels in brain (Roth & Meltzer,1995). 
Whatever the mechanism the fluoxetine was 
effective and well tolerated by the patients. 
Both the non-responders were male and 
treatment resistant patients. One showed 
response to clozapine and was maintained on 
• clozapine 500 mg while other had history of non-
response to clozapine. Their OC symptoms were 
present prior to the administration of clozapine. 
The mechanism of non response in one patient 
could be the antagonistic effects of fluoxetine 
and clozapine on the serotonin system. It is also 
possible that they may respond to a different 
antiobsessional agent as both of them were given 
fluoxetine as a first antiobsessional agent. 
The major limitations of the study were 
open trial, absence of the comparison group and 
small sample size. The preliminary findings 
suggest that fluoxetine was safe and effective 
in treatment of OC symptoms in schizophrenia. 
However mere is the need of controlled trials on 
larger sample to confirm the findings of this study. 
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